Roots Analysis has done a detailed
study on
To order this 500+ page report, which features 185+ figures
and 220+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html
Key Market Insights
§ Eminent representatives from different biopharmaceutical
companies confirm the growing interest in stem cell therapy research, highlighting
the prevalent and anticipated trends in ongoing R&D activities.
§ More
than 120 industry players are engaged in evaluating the potential of over 280
stem cell therapy products for the treatment of a variety of disease
indications.
§ The
pipeline features a variety of marketed / clinical therapies being evaluated
across different stages targeting various types of stem cells; these products
are designed for administration via diverse routes of administration.
§ Stem
cell therapies have demonstrated the applicability across over 25 unique
therapeutic areas; cardiovascular, neurological, musculoskeletal and autoimmune
/ inflammatory disorders are presently the primary focus.
§ Several
organizations have extended financial support to aid research efforts in this
domain; the current focus is on the evaluation of different stem cell types
across multiple clinical conditions.
§ In the
last few years, over 540 clinical trials, evaluating various types of stem cell
therapies in more than 52,000 patients, have been initiated; most of these
trials are presently being conducted in centers across the US.
§ As
several therapy candidates progress towards regulatory approval, developers are
exploring diverse commercialization strategies to be implemented across
different stages of a product’s launch cycle.
§ Owing to
the rising demand for stem cell therapies, and challenges associated with
manufacturing and scale up, industry players have demonstrated preferences to
engage the services of contract service providers.
§ More
than 80 industry / non-industry players, based in different regions across the
globe, claim to provide contract development and manufacturing services to
cater to the specific unmet needs of therapy developers.
§ Future
growth of the market is likely to be driven by the success of different types
of stem cell therapies, which are allogeneic and autologous in nature, as
stakeholders continue to remain optimistic about proprietary products.
§ The
foreseen future market opportunity, based on the revenue generation potential
of such therapies, is anticipated to be distributed across different
therapeutic areas, end-users and key geographical regions.
§ Products
based on bone marrow derived adult stem cells are likely to continue to
dominate the market in the mid-long term; adoption of therapies administered
via novel routes of administration is likely to gradually rise.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cell Therapies
3.2.1. Historical Evolution of Stem Cell Research
3.2.2. Classification of Stem Cells
3.2.2.1. Based on Source of Stem Cell
3.2.2.2. Based on Origin of Stem Cell
3.2.2.3. Based on Potency of Stem Cell
3.2.3. Administration of Stem Cell Therapies
3.2.4. Applications of Stem Cell Therapies
3.2.5. Challenges Associated with Development of
Stem Cell Therapies
3.3. Regulatory Guidelines for Stem Cell
Therapies
3.3.1. Current Scenario
3.3.2. Regulatory Guidelines in North America
3.3.3. Regulatory Guidelines in Europe
3.3.4. Regulatory Guidelines in Japan
3.4. Prevalent Trends Related to Stem Cell
Therapies
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity
3.5. Growth Drivers and Roadblocks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies: Marketed and
Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Source of Stem Cell
4.2.3. Analysis by Origin of Stem Cell
4.2.4. Analysis by Type of Stem Cell
4.2.5. Analysis by Lineage of Stem Cell
4.2.6. Analysis by Potency of Stem Cell
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Route of Administration
4.3. Stem Cell Therapies: Additional
Information
4.3.1. Information on Dosage and Commercial Rights
4.3.2. Information on Designations Awarded
4.4. Stem Cell Therapies: List of Technology
Platforms
4.5. Stem Cell Therapies: List of Therapy
Developers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Company Size and Location of
Headquarters
4.5.5. Leading Drug Developers: Analysis by Number
of Stem Cell Therapies
4.5.6. Leading Drug Developers: 4D Bubble Analysis
based on Strength of Pipeline, Target Indication and Company Size
4.6. Heptagon Representation: Analysis by Phase
of Development and Key Therapeutic Area
4.7. Grid Representation: Analysis by Phase of
Development, Source of Stem Cell and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic
Area and Size of the Company
4.9. World Map Representation: Analysis of
Regional Activity
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Anterogen
5.2.1. Company Overview
5.2.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.2.3. Recent Developments and Future Outlook
5.3. Athersys
5.3.1. Company Overview
5.3.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.3.3. Recent Developments and Future Outlook
5.4. CHA Biotech
5.4.1. Company Overview
5.4.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.4.3. Recent Developments and Future Outlook
5.5. Cytopeutics
5.5.1. Company Overview
5.5.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.5.3. Recent Developments and Future Outlook
5.6. Hope Biosciences
5.6.1. Company Overview
5.6.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.6.3. Recent Developments and Future Outlook
5.7. Mesoblast
5.7.1. Company Overview
5.7.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.7.3. Recent Developments and Future Outlook
5.8. Pluristem Therapeutics
5.8.1. Company Overview
5.8.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.8.3. Recent Developments and Future Outlook
5.9. Takeda Pharmaceutical
5.9.1. Company Overview
5.9.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.9.3. Recent Developments and Future Outlook
5.10. TICEBA
5.10.1. Company Overview
5.10.2. Product Portfolio: Clinical-Stage Stem Cell
Therapies
5.10.3. Recent Developments and Future Outlook
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Autoimmune / Inflammatory Disorders
6.2.1. Crohn’s Disease
6.2.1.1. Disease Description
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Options
6.2.1.4. Side Effects of Current Treatment Options
6.2.1.5. Stem Cell Therapies for Crohn’s Disease
6.2.2. Ulcerative Colitis
6.2.2.1. Disease Description
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Options
6.2.2.4. Side Effects of Current Treatment Options
6.2.2.5. Stem Cell Therapies for Ulcerative Colitis
6.3. Cardiovascular Disorders
6.3.1. Critical Limb Ischemia
6.3.1.1. Disease Description
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Options
6.3.1.3.1. Pharmacological
Interventions
6.3.1.3.2. Endovascular
Treatments
6.3.1.3.3. Surgical
Interventions
6.3.1.4. Stem Cell Therapies for Critical Limb Ischemia
6.3.2. Heart Failure
6.3.2.1. Disease Description
6.3.2.2. Epidemiology
6.3.2.3. Current Treatment Options
6.3.2.3.1. Pharmacological
Interventions
6.3.2.3.2. Therapeutic
Devices
6.3.2.3.3. Surgical
Interventions
6.3.2.4. Stem Cell Therapies for Heart Failure
6.3.3. Myocardial Infarction
6.3.3.1. Disease Description
6.3.3.2. Epidemiology
6.3.3.3. Current Treatment Options
6.3.3.3.1. Pharmacological
Interventions
6.3.3.3.2. Surgical
Interventions
6.3.3.4. Stem Cell Therapies for Myocardial Infarction
6.4. Dermatological Disorders
6.4.1. Acne Vulgaris
6.4.1.1. Disease Description
6.4.1.2. Epidemiology
6.4.1.3. Current Treatment Options
6.4.1.4. Side Effects of Current Treatment Options
6.4.1.5. Stem Cell Therapies for Acne Vulgaris
6.5. Metabolic Disorders
6.5.1. Diabetes
6.5.1.1. Disease Description
6.5.1.2. Associated Health Risks / Complications
6.5.1.3. Epidemiology
6.5.1.4. Disease Diagnosis
6.5.1.5. Current Treatment Options
6.5.1.5.1. Insulin
Therapies
6.5.1.5.2. Non-Insulin
Therapies
6.5.1.6. Side Effects of Current Treatment Options
6.5.1.7. Stem Cell Therapies for Diabetes
6.5.2. Non-alcoholic Steatohepatitis (NASH)
6.5.2.1. Disease Description
6.5.2.2. Epidemiology
6.5.2.3. Current Treatment Options
6.5.2.4. Stem Cell Therapies for NASH
6.6. Oncological Disorders
6.6.1. Bladder Cancer
6.6.1.1. Disease Description
6.6.1.2. Epidemiology
6.6.1.3. Current Treatment Options
6.6.1.4. Stem Cell Therapies for Bladder Cancer
6.6.2. Breast Cancer
6.6.2.1. Disease Description
6.6.2.2. Epidemiology
6.6.2.3. Current Treatment Options
6.6.2.4. Stem Cell Therapies for Breast Cancer
6.6.3. Colorectal Cancer
6.6.3.1. Disease Description
6.6.3.2. Epidemiology
6.6.3.3. Current Treatment Options
6.6.3.4. Side Effects of Current Treatment Options
6.6.3.5. Stem Cell Therapies for Colorectal Cancer
6.6.4. Kidney Cancer
6.6.4.1. Disease Description
6.6.4.2. Epidemiology
6.6.4.3. Current Treatment Options
6.6.4.4. Stem Cell Therapies for Kidney Cancer
6.6.5. Liver Cancer
6.6.5.1. Introduction
6.6.5.2. Epidemiology
6.6.5.3. Current Treatment Options
6.6.5.4. Stem Cell Therapies for Liver Cancer
6.6.6. Lung Cancer
6.6.6.1. Disease Description
6.6.6.2. Epidemiology
6.6.6.3. Current Treatment Options
6.6.6.4. Side Effects of Current Treatment Options
6.6.6.5. Stem Cell Therapies for Lung Cancer
6.6.7. Ovarian Cancer
6.6.7.1. Disease Description
6.6.7.2. Epidemiology
6.6.7.3. Current Treatment Options
6.6.7.4. Stem Cell Therapies for Ovarian Cancer
6.6.8. Pancreatic Cancer
6.6.8.1. Disease Description
6.6.8.2. Epidemiology
6.6.8.3. Current Treatment Options
6.6.8.4. Stem Cell Based Therapies for Pancreatic Cancer
6.7. Neurological Disorders
6.7.1. Alzheimer’s Disease
6.7.1.1. Disease Description
6.7.1.2. Epidemiology
6.7.1.3. Symptoms of the Disease
6.7.1.4. Causes of Alzheimer’s Disease
6.7.1.5. Stages of Alzheimer’s Disease
6.7.1.6. Current Treatment Options
6.7.1.7. Stem Cell Therapies for Alzheimer’s Disease
6.7.2. Parkinson’s Disease
6.7.2.1. Disease Description
6.7.2.2. Epidemiology
6.7.2.3. Current Treatment Options
6.7.2.3.1. Pharmacological
Management of Parkinson’s Disease
6.7.2.3.2. Non-Pharmacological
Management of Parkinson’s Disease
6.7.2.3.3. Management
of Parkinson’s Disease Using Dietary Supplements
6.7.2.4. Stem Cell Therapies for Parkinson’s Disease
7. ASSESSMENT OF RELATIVE COMPETITION AND
GROWTH OPPORTUNITIES
7.1. Chapter Overview
7.2. Assumptions and Methodology
7.3. Analysis of Relative Competition and
Growth Opportunities
7.3.1. Established Therapeutic Areas in Emerging
Regions
7.3.2. Established Therapeutic Areas in Established
Regions
7.3.3. Emerging Therapeutic Areas in Emerging
Regions
7.3.4. Emerging Therapeutic Areas in Established
Regions
8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Stem Cell Therapies: Analysis of Grants Awarded
by the National Institutes of Health (NIH)
8.3.1. Analysis by Year of Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Funding Institute Center
8.3.5. Analysis by Support Period
8.3.6. Analysis by Funding Institute Center and
Support Period
8.3.7. Most Popular NIH Spending Categorizations
8.3.8. Analysis by Funding Mechanism
8.3.9. Emerging Focus Areas
8.3.10. Analysis by Source of Stem Cell
8.3.11. Analysis by Origin of Stem Cell
8.3.12. Analysis by Type of Stem Cell
8.3.13. Analysis by Lineage of Stem Cell
8.3.14. Analysis by Potency of Stem Cell
8.3.15. Analysis by Therapeutic Area
8.3.16. Analysis by Type of Grant Application
8.3.17. Popular NIH Departments
8.3.18. Analysis by Study Section
8.3.19. Analysis by Types of Recipient Organizations
8.3.20. Popular Recipient Organizations
8.3.21. Analysis by Grant Mechanism
8.3.22. Prominent Program Officers
8.3.23. Regional Distribution of Recipient
Organizations
8.4. Grant Attractiveness Analysis
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Stem Cell Therapies: Clinical Trial
Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Number of Patients Enrolled by
Trial Registration Year
9.3.4. Analysis by Study Design
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Sponsor / Collaborator
9.3.7. Leading Industry Sponsors: Based on Number of
Registered Trials
9.3.8. Analysis by Trial Focus
9.3.9. Analysis by Type of Stem Cell
9.3.10. Analysis by Therapeutic Area
9.3.11. Analysis by Type of Stem Cell and Therapeutic
Area
9.3.12. Geographical Analysis by Number of Clinical
Trials
9.3.13. Geographical Analysis by Trial Recruitment
Status
9.3.14. Geographical Analysis by Enrolled Patient
Population
10. STEM CELL MANUFACTURING MARKET LANDSCAPE
AND KPIs FOR EVALUATING CONTRACT
SERVICES PARTNERS
10.1. Chapter Overview
10.2. Stem Cell Therapy Manufacturing
10.2.1. Need for Stem Cell Therapy Contract
Manufacturing
10.2.2. Advantages of Outsourcing Stem Cell Therapy
Manufacturing
10.2.3. Guidelines for Selecting a Contract
Manufacturing Organization (CMO) Partner
10.2.4. Stem Cell Therapy CMOs: List of Industry
Players
10.2.4.1. Analysis by
Year of Establishment
10.2.4.2. Analysis by
Company Size
10.2.4.3. Analysis by
Scale of Stem Cell Manufacturing
10.2.4.4. Analysis by
Location of Headquarters
10.2.4.5. Analysis by
Location of Manufacturing Facilities
10.2.4.6. Analysis by
Types of Services Offered
10.2.4.7. Analysis by
Source and Origin of Stem Cell
10.2.5. Stem Cell Therapy CMOs: List of Non-Industry
Players
10.2.5.1. Analysis by
Year of Establishment
10.2.5.2. Analysis by
Scale of Stem Cell Manufacturing
10.2.5.3. Analysis by
Location of Headquarters
10.2.5.4. Analysis by
Location of Manufacturing Facilities
10.2.5.5. Analysis by
Types of Services Offered
10.2.5.6. Analysis by
Source and Origin Stem Cell
10.3. Stem Cell Therapy Manufacturing: KPI Analysis
10.3.1. KPI Definitions
10.3.1.1. Financial
Indicators
10.3.1.1.1. Big
Pharma Perspective
10.3.1.1.2. Contract
Manufacturers’ Perspective
10.3.1.2. Process and
Capability Indicators
10.3.1.2.1. Big
Pharma Perspective
10.3.1.2.2. Contract
Manufacturers’ Perspective
10.3.1.3. Market
Reputation Indicators
10.3.1.3.1. Big
Pharma Perspective
10.3.1.3.2. Contract
Manufacturers’ Perspective
10.4. Concluding Remarks
11. STEM CELL THERAPY DEVELOPERS AND CMOs:
OPPORTUNITY ASSESSMENT
11.1. Chapter Overview
11.2. Therapy Developers and CMOs in North
America
11.2.1. Gap Analysis by Scale of Stem Cell
Manufacturing
11.2.2. Gap Analysis by Source of Stem Cell
11.2.3. Gap Analysis by Origin of Stem Cell
11.3. Therapy Developers and CMOs in Europe
11.3.1. Gap Analysis by Scale of Stem Cell
Manufacturing
11.3.2. Gap Analysis by Source of Stem Cell
11.3.3. Gap Analysis by Origin of Stem Cell
11.4. Therapy Developers and CMOs in Asia-Pacific
and Rest of the World
11.4.1. Gap Analysis by Scale of Stem Cell Manufacturing
11.4.2. Gap Analysis by Source of Stem Cell
11.4.3. Gap Analysis by Origin of Stem Cell
11.5. Concluding Remarks
12. KEY COMMERCIALIZATION STRATEGIES
12.1. Chapter Overview
12.2. Successful Drug Launch Strategy: ROOTS
Framework
12.3. Successful Drug Launch Strategy: Product
Differentiation
12.4. Commonly Adopted Commercialization
Strategies based on Stage of Product Development
12.5. Key Approved Stem Cell Therapies: Profiles
12.5.1. CARTISTEM®
12.5.2. HiQCell®
12.5.3. Prochymal®
12.5.4. Strimvelis®
12.6. Key Commercialization Strategies Adopted by
Stem Cell Therapy Developers
12.6.1. Strategies Adopted before Therapy Approval
12.6.1.1. Participation
in Global Events
12.6.1.2. Collaboration
with Stakeholders and Pharmaceutical Firms
12.6.1.3. Seeking
Approval for Multiple Target Indications
12.6.1.4. Seeking
Special Therapy Designations and Other Credentials
12.6.1.5. Leveraging
Uniqueness to Establish Competitive Edge
12.6.1.6. Anticipation
of Likely Market Dynamics and Trends
12.6.1.7. Outsourcing
Manufacturing Operations
12.6.2. Strategies Adopted Post Therapy Approval
12.6.2.1. Geographical
Expansion
12.6.2.2. Participation
in Global Events
12.6.2.3. Patient
Assistance Programs
12.6.2.4. Miscellaneous
Programs
12.7. Opportunities and Challenges with
Unapproved Therapies
12.8. Concluding Remarks
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology and Key Assumptions
13.4. Overall Stem Cell Therapies Market,
2020-2030
13.4.1. Stem Cell Therapies Market: Distribution by
Source of Stem Cell
13.4.1.1. Stem Cell
Therapies Market for Allogeneic Therapies, 2020-2030
13.4.1.2. Stem Cell
Therapies Market for Autologous Therapies, 2020-2030
13.4.2. Stem Cell Therapies Market: Distribution by
Origin of Stem Cell
13.4.2.1. Stem Cell
Therapies Market for Adult Stem Cells, 2020-2030
13.4.2.2. Stem Cell
Therapies Market for Embryonic Stem Cells, 2020-2030
13.4.3. Stem Cell Therapies Market: Distribution by
Type of Stem Cell
13.4.3.1. Stem Cell
Therapies Market for Hematopoietic Stem Cells, 2020-2030
13.4.3.2. Stem Cell
Therapies Market for Mesenchymal Stem Cells, 2020-2030
13.4.3.3. Stem Cell
Therapies Market for Progenitor Cells, 2020-2030
13.4.3.4. Stem Cell
Therapies Market for Others, 2020-2030
13.4.4. Stem Cell Therapies Market: Distribution by
Lineage of Stem Cell
13.4.4.1. Stem Cell
Therapies Market for Adipose Tissue Derived Stem Cells, 2020-2030
13.4.4.2. Stem Cell
Therapies Market for Bone Marrow Derived Stem Cells, 2020-2030
13.4.4.3. Stem Cell
Therapies Market for Cord Blood Derived Stem Cells, 2020-2030
13.4.4.4. Stem Cell
Therapies Market for Others, 2020-2030
13.4.5. Stem Cell Therapies Market: Distribution by
Route of Administration
13.4.5.1. Stem Cell
Therapies Market for Intraarticular Therapies, 2020-2030
13.4.5.2. Stem Cell
Therapies Market for Intracoronary Therapies, 2020-2030
13.4.5.3. Stem Cell
Therapies Market for Intramuscular Therapies, 2020-2030
13.4.5.4. Stem Cell
Therapies Market for Intramyocardial Therapies, 2020-2030
13.4.5.5. Stem Cell
Therapies Market for Intrathecal Therapies, 2020-2030
13.4.5.6. Stem Cell
Therapies Market for Intravenous Therapies, 2020-2030
13.4.5.7. Stem Cell
Therapies Market for Surgical Implants, 2020-2030
13.4.5.7. Stem Cell
Therapies Market for Others, 2020-2030
13.4.6. Stem Cell Therapies Market: Distribution by
Therapeutic Area
13.4.6.1. Stem Cell
Therapies Market for Autoimmune / Inflammatory Disorders, 2020-2030
13.4.6.2. Stem Cell
Therapies Market for Cardiovascular Disorders, 2020-2030
13.4.6.3. Stem Cell
Therapies Market for Metabolic Disorders, 2020-2030
13.4.6.4. Stem Cell
Therapies Market for Musculoskeletal Disorders, 2020-2030
13.4.6.5. Stem Cell
Therapies Market for Neurological Disorders, 2020-2030
13.4.6.6. Stem Cell
Therapies Market for Oncological Disorders, 2020-2030
13.4.6.7. Stem Cell
Therapies Market for Ophthalmic Disorders, 2020-2030
13.4.6.8. Stem Cell
Therapies Market for Others, 2020-2030
13.4.7. Stem Cell Therapies Market: Distribution by
End-Users
13.4.7.1. Stem Cell
Therapies Market for Ambulatory Surgery Centers, 2020-2030
13.4.7.2. Stem Cell
Therapies Market for Hospitals, 2020-2030
13.4.7.3. Stem Cell
Therapies Market for Specialty Clinics, 2020-2030
13.4.8. Stem Cell Therapies Market: Distribution by
Key Geographical Regions
13.4.8.1. Stem Cell
Therapies Market in North America, 2020-2030
13.4.8.2. Stem Cell
Therapies Market in Europe, 2020-2030
13.4.8.3. Stem Cell
Therapies Market in Asia-Pacific and Rest of the World, 2020-2030
13.5. Concluding Remarks
14. CONCLUSION
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Seraxis
15.2.1. Company Snapshot
15.2.2. Interview Transcript: William L Rust, Founder
and Chief Executive Officer
15.3. Xcelthera
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Xuejun Huang Parsons,
Chief Executive Officer
15.4. Kadimastem
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Michel Revel, Co-Founder
/ Chief Scientist and Galit Mazooz-Perlmuter, Director,
Business Development
15.5. Heartseed
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Kikuo Yasui, Director
and Chief Operating Officer
15.6. University of Rostock
15.6.1. Organization Snapshot
15.6.2. Interview Transcript: Gustav Steinhoff,
Director and Chairman, Department of Cardiac Surgery
15.7. Bio Elpida
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Gilles Devillers,
President
15.8. Roslin Cell Therapies
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Fiona Bellot, Business
Development Manager
15.9. University of Minnesota
15.9.1. Organization Snapshot
15.9.2. Interview Transcript: David Mckenna, Professor
and American Red Cross Chair in Transfusion Medicine
15.10. Waisman Biomanufacturing
15.10.1.Company
Snapshot
15.10.2.Interview
Transcript: Brian Dattilo, Manager of Business Development
15.11. YposKesi
15.11.1.Company
Snapshot
15.11.2.Interview
Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and
Development
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND
ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
